Challenges in mental health: biomarkers and personalized medicine (Part 1)

Written by Lauren Pulling

As part of #NCMentalHealthMonth, we recently sat down with Expert Panel member Gabriel Vargas (Amgen, San Francisco, CA, USA) to discuss the current status of biomarker development and personalized treatment for psychiatric disorders. Gabriel has previously held posts at the University of California at San Francisco (UCSF; CA, USA) and Roche (CA, USA and Switzerland), and is now Executive Medical Director and Neuroscience Therapeutic Area Head, Early Development at Amgen in San Francisco. His research at UCSF centered around membrane trafficking of GPCRs, in particular dopamine receptors, as well as clinical work with the schizophrenia patient population and the creation...

To view the full article, please register now for access

It's completely free